Revvity, Inc. Q2 2026 Earnings Call Summary

Revvity reported better-than-expected second-quarter results, which management attributed to an improving spending environment across the pharmaceutical and biotechnology sectors. The company has now recorded three consecutive quarters of strengthening end-market conditions. Full-year organic growth guidance was increased to a range of 4% to 5%, reflecting heightened confidence in the durability of the pharma and biotech recovery observed during the first half of the year.
Orders are climbing f